Xinmailong Injection inhibits the progression of heart failure by inhibiting ERK1/2, Akt/GSK3β, and GATA4 signaling pathways, reduces posterior left ventricular wall hypertrophy and increases left ventricular ejection fraction (LVEF) and left ventricular shortening (LVFS) [71]. The gene discussed is AKT1; the disease is heart failure.